These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32202691)

  • 1. Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience.
    Teusink-Cross A; Davies SM; Grimley MS; Chandra S; Flannery A; Dandoy CE; Nelson AS; Marsh RA; Jacoby B; Lane A; Khandelwal P
    Pediatr Transplant; 2020 May; 24(3):e13692. PubMed ID: 32202691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
    Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C
    Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
    Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
    Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
    Miklos D; Cutler CS; Arora M; Waller EK; Jagasia M; Pusic I; Flowers ME; Logan AC; Nakamura R; Blazar BR; Li Y; Chang S; Lal I; Dubovsky J; James DF; Styles L; Jaglowski S
    Blood; 2017 Nov; 130(21):2243-2250. PubMed ID: 28924018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study.
    Carpenter PA; Kang HJ; Yoo KH; Zecca M; Cho B; Lucchini G; Nemecek ER; Schultz KR; Stepensky P; Chaudhury S; Oshrine B; Khaw SL; Harris AC; Verna M; Zubarovskaya L; Lee Y; Wahlstrom J; Styles L; Shaw PJ; Dalle JH
    Transplant Cell Ther; 2022 Nov; 28(11):771.e1-771.e10. PubMed ID: 36044977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of inflammatory myopathy in graft vs host disease - A potential role for ibrutinib.
    Wilkinson M; Yeung D; Limaye V
    Neuromuscul Disord; 2021 Sep; 31(9):865-869. PubMed ID: 34334272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
    Waller EK; Miklos D; Cutler C; Arora M; Jagasia MH; Pusic I; Flowers MED; Logan AC; Nakamura R; Chang S; Clow F; Lal ID; Styles L; Jaglowski S
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2002-2007. PubMed ID: 31260802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
    Akpek G; Lee SM; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Ibrutinib for Chronic Graft-Versus-Host Disease: A Systematic Review.
    Santosa D; Rizky D; Tandarto K; Kartiyani I; Yunarvika V; Ardini DNE; Setiawan B; Pangarsa EA; Suharti C
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4025-4033. PubMed ID: 38156834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib for the Treatment of Chronic GVHD and Overlap Syndrome in Children and Young Adults.
    Wang YM; Teusink-Cross A; Elborai Y; Krupski MC; Nelson AS; Grimley MS; Flannery A; Mehta PA; Bleesing JJ; Chandra S; Kumar AR; Myers KC; Davies SM; Khandelwal P
    Transplantation; 2022 Feb; 106(2):412-419. PubMed ID: 33795598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
    Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
    Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
    Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
    Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
    Gonzalez RM; Pidala J
    Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes.
    Linn SM; Novitzky-Basso I; Abduljalil O; Pasic I; Lam W; Law A; Michelis FV; Gerbitz A; Viswabandya A; Lipton J; Kumar R; Mattsson J; Kim DDH
    Hematol Oncol Stem Cell Ther; 2023 Jul; 17(1):60-71. PubMed ID: 37581458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
    Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
    Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency and Toxicity of Imatinib Mesylate Combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease: A Single-Center, Prospective, Single-Arm, Open-Label Study.
    Chen T; Li J; Wei X; Yao H; Zhu L; Liu J; Liu Y; Wang P; Feng Y; Gao S; Liu H; Wang L; Zhao L; Gao L; Zhang C; Gao L; Zhang X; Kong P
    Acta Haematol; 2024; 147(5):499-510. PubMed ID: 38232716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
    Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
    Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.